Chemomab Therapeutics Ltd at Oppenheimer Healthcare Conference (Virtual) Transcript
Good morning, everyone, and welcome as we continue with day three of Oppenheimer's 33rd Annual Healthcare Conference. I'm Jeff Jones, a senior analyst here on the biotechnology team, and I'm delighted to welcome the Chemomab team with Dale Pfost, CEO as the lead presenter but we have the whole team here.
Dale, I will hand it off to you to take us through the Chemomab store.
Thank you. Today, I'll be joined by Adi Mor, our co-founder and CSO; Matt Frankel, our CMO; Don Marvin, our EVP, COO, and CFO; and Barbara Lindheim, our VP of Strategic Communications. Please refer to our forward-looking statements and risk factors, including those on file with the SEC.
Here's why we are so excited about Chemomab, in four key points we'll be covering today. We have a unique target with disease-modifying potential. We've worked towards de-risking our programs through nearly 10 years of extensive preclinical studies, reinforced by four completed clinical trials. We
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
